Skip to main content
TipRanks
Go Ultimate75% OFF

Metlife (MWZ) AI Stock Analysis

1 Followers
DE:MWZ

Metlife

(XETRA:MWZ)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Broad-based operating growthGrowth across all operating segments indicates that MetLife is not dependent on a single product or geography for expansion. This diversification can support more resilient premium and fee revenue, broaden cross-selling opportunities, and strengthen earnings durability through varying insurance and economic cycles.
Negative Factors
Higher leverageThe increase in leverage reduces balance-sheet flexibility and leaves less capacity to absorb adverse insurance or investment outcomes. Higher debt can also increase financing costs and constrain capital allocation, making the company more sensitive to earnings pressure or changes in financial conditions.

Metlife (MWZ) vs. iShares MSCI Germany ETF (EWG)

-10%0%10%20%30%40%50%DE:MWZ+46.62%EWG+9.20%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
EUR 64.51B
Dividend Yield
2.28%
Average Volume (3M)
25
Price to Earnings (P/E)
13.3
Beta (1Y)
0.63
Revenue Growth
9.33%
EPS Growth
36.70%
Country
Germany
Employees
46,000
Sector
Financial
Sector Strength
68
Industry
Insurance - Life

Metlife Business Overview & Revenue Model

Company Description

MetLife, Inc. operates as a leading global financial services entity, delivering an extensive array of services encompassing insurance, annuities, employee benefits, and asset management. The company manages its operations through five primary divisi...

Metlife Earnings Call Summary

Earnings Call Date:Nov 04, 2026(Q3-2026)|% Change Since:2.00%|Next Earnings Date:Feb 03, 2027
Earnings Call SentimentPositive

The call was strongly positive. MetLife reported record adjusted EPS, 22% year-to-date adjusted EPS growth, adjusted ROE above target, broad-based segment growth, strong capital generation, substantial shareholder returns and disciplined expense management. The main challenges were lighter pension risk transfer activity, the Latin America encaje headwind, Asia's quarterly sales decline, higher expenses and some MIM sequential AUM pressure, but management characterized several of these items as timing-related or manageable and maintained its outlook.

Positive Updates

Record Adjusted Earnings and Strong Year-to-Date Performance
MetLife delivered its highest adjusted earnings per share quarter ever. Third-quarter adjusted earnings were $1.8 billion, or $2.78 per share; excluding $46 million of notable items, adjusted earnings were $1.8 billion, up 17% year over year, and adjusted EPS was $2.85, up 22%. Year-to-date adjusted EPS excluding notable items was up 22%, with adjusted return on equity above 17%.

Negative Updates

Actuarial Review Reduced Adjusted Earnings
The annual global actuarial assumption review and other insurance adjustments reduced adjusted earnings by $46 million, or $0.07 per share. RIS had an unfavorable impact from lower mortality, largely offset by favorable economic and mortality updates in Asia.

Company Guidance

Management expects the full-year direct expense ratio to beat the 12.1% target, adjusted ROE to exceed the 15% to 17% target range, and the 2029 direct expense ratio to be 11.3%; Group Benefits’ 2026 target range is 83% to 88% for group life mortality and 70% to 75% for non-medical health, while RIS adjusted earnings are expected to finish slightly north of the midpoint of the $1.6 billion to $1.8 billion outlook range, assuming normal VII in the fourth quarter. RIS total investment spread guidance is 100 to 120 basis points, core spread is expected to remain within 95 to 100 basis points, and fourth-quarter VII is expected to be within the $100 million to $120 million range; company-wide fourth-quarter VII is assumed at the normal $400 million run rate, with full-year VII expected to exceed approximately $1.6 billion. MIM adjusted earnings are expected within the $240 million to $280 million target range, the effective tax rate guidance range is 24% to 26%, the free cash flow ratio target is 65% to 75%, and holding company cash and liquid assets are targeted within a $3 billion to $4 billion buffer.

Metlife Risk Analysis

Metlife disclosed 46 risk factors in its most recent earnings report. Metlife reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

0 New Risks

Metlife Peers Comparison

Overall Rating

UnderperformOutperform
Sector (68)

Financial Indicators

DE:MWZ against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
VOYAVOYA75Outperform$9.11B16.2414.78%1.84%-0.31%6.72%
AFLAFL73Outperform$63.12B18.6611.85%1.89%-6.22%-10.65%
PRUPRU69Neutral$42.38B11.0812.05%4.49%6.46%50.56%
Sector *68Neutral$18.00B11.429.92%3.81%9.73%1.22%
LNCLNC64Neutral$7.99B2.5031.63%4.29%12.34%45.09%
UNMUNM51Neutral$12.37B56.622.23%2.42%-4.15%-72.51%

* Financial Sector Average

Performance Comparison

0%20%40%DE:MWZAFLLNCPRUUNMVOYADec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
DE:MWZ and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DE:MWZMetlife92.0228.4644.78%
AFLAFLAC Incorporated128.0818.6117.00%
LNCLincoln National41.363.579.45%
PRUPrudential Financial122.9124.1524.45%
UNMUnum Group78.683.734.98%
VOYAVoya Financial102.4734.4650.67%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.